Clinical Research Directory
Browse clinical research sites, groups, and studies.
Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo
Sponsor: Kafrelsheikh University
Summary
This randomized comparative study will evaluate the efficacy and safety of topical ruxolitinib 1.5% cream compared with topical tacrolimus 0.1% ointment, each combined with 308-nm excimer laser therapy, in patients aged 12 years or older with stable localized non-segmental facial vitiligo. Forty participants will be randomly assigned in a 1:1 ratio to receive one of the topical treatments twice daily for 24 weeks plus excimer laser treatment. Clinical, dermoscopic, patient-reported, and histopathological outcomes will be assessed before and after treatment, with follow-up for recurrence.
Official title: Clinical and Histopathological Evaluation of Excimer Laser With Topical Ruxolitinib 1.5% or Tacrolimus 0.1% in Localized Vitiligo: A Randomized Comparative Study
Key Details
Gender
All
Age Range
12 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-07-01
Completion Date
2027-01-01
Last Updated
2026-11-02
Healthy Volunteers
No
Conditions
Interventions
Tacrolimus 0.1% ointment
Topical application every 12 hours for 24 weeks.
Ruxolitinib 1.5% cream
Topical application every 12 hours for 24 weeks
308-nm excimer laser
10 treatment sessions, twice weekly, administered to both groups.
Locations (1)
Kafrelsheikh University Hospital
Kafr ash Shaykh, Egypt